• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Empagliflozin for non-diabetic metabolic dysfunction-associated steatotic liver disease: a promising therapeutic agent in transition.

作者信息

El-Kassas Mohamed, Liu Hongqun, Lee Samuel S

机构信息

Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.

Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA), Cairo, Egypt.

出版信息

Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):651-654. doi: 10.21037/hbsn-2025-250. Epub 2025 Jul 25.

DOI:10.21037/hbsn-2025-250
PMID:40893754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12393100/
Abstract
摘要

相似文献

1
Empagliflozin for non-diabetic metabolic dysfunction-associated steatotic liver disease: a promising therapeutic agent in transition.恩格列净用于非糖尿病性代谢功能障碍相关脂肪性肝病：一种正处于转变中的有前景的治疗药物。
Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):651-654. doi: 10.21037/hbsn-2025-250. Epub 2025 Jul 25.
2
Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.恩格列净对非糖尿病代谢功能障碍相关脂肪性肝病患者肝脂肪的影响：一项随机、双盲、安慰剂对照试验。
Hepatology. 2024 Oct 1;80(4):916-927. doi: 10.1097/HEP.0000000000000855. Epub 2024 Mar 27.
3
The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对2型糖尿病和代谢相关脂肪性肝病患者经磁共振成像-质子密度脂肪分数（MRI-PDFF）检测的肝脂肪变性的影响。
Intern Emerg Med. 2025 Jun;20(4):1025-1033. doi: 10.1007/s11739-025-03902-w. Epub 2025 Mar 14.
4
Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial.噻唑烷二酮与钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者代谢功能障碍相关脂肪性肝病的协同益处：一项为期24周的开放标签随机对照试验
BMC Med. 2025 May 7;23(1):266. doi: 10.1186/s12916-025-04017-x.
5
Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病中代谢功能障碍相关脂肪性肝病的长期影响：一项通过磁共振成像的回顾性分析
Endocr J. 2024 Aug 8;71(8):767-775. doi: 10.1507/endocrj.EJ24-0005. Epub 2024 May 30.
6
Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.用于诊断代谢功能障碍相关脂肪性肝病的质子密度脂肪分数
Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001318.
7
Limited preventive effects of empagliflozin against metabolic dysfunction-associated steatotic liver disease in a mouse model of fast food diet.在快餐饮食小鼠模型中，恩格列净对代谢功能障碍相关脂肪性肝病的预防作用有限。
Hormones (Athens). 2024 Dec 19. doi: 10.1007/s42000-024-00621-3.
8
Nonalcoholic Fatty Liver非酒精性脂肪肝
9
Liver and pancreatic fat fractions as predictors of disease severity in acute pancreatitis: an MRI IDEAL-IQ study.肝脏和胰腺脂肪分数作为急性胰腺炎疾病严重程度的预测指标：一项MRI IDEAL-IQ研究
Abdom Radiol (NY). 2025 Jan 30. doi: 10.1007/s00261-025-04809-y.
10
The diagnostic value of MRI-PDFF in hepatic steatosis of patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.MRI-PDFF对代谢功能障碍相关脂肪性肝病患者肝脂肪变性的诊断价值：一项系统评价和荟萃分析
BMC Gastroenterol. 2025 Jul 1;25(1):451. doi: 10.1186/s12876-025-04017-4.

本文引用的文献

1
Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta-Analysis.降糖药物在代谢功能障碍相关脂肪性肝病（MASLD）中的疗效：一项系统评价和网状荟萃分析
J Evid Based Med. 2025 Jun;18(2):e70021. doi: 10.1111/jebm.70021.
2
Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis.代谢功能障碍相关脂肪性肝病和脂肪性肝炎的全球共识建议
Gastroenterology. 2025 Apr 11. doi: 10.1053/j.gastro.2025.02.044.
3
Resmetirom: The First Disease-Specific Treatment for MASH.
雷斯美洛：非酒精性脂肪性肝炎的首个疾病特异性治疗药物。
Int J Endocrinol. 2025 Feb 26;2025:6430023. doi: 10.1155/ije/6430023. eCollection 2025.
4
Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: Current and emerging therapeutic options.代谢功能障碍相关脂肪性肝病及相关疾病的药物治疗：当前及新兴治疗选择
Pharmacol Rev. 2025 Mar;77(2):100018. doi: 10.1016/j.pharmr.2024.100018. Epub 2024 Nov 22.
5
The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对2型糖尿病和代谢相关脂肪性肝病患者经磁共振成像-质子密度脂肪分数（MRI-PDFF）检测的肝脂肪变性的影响。
Intern Emerg Med. 2025 Jun;20(4):1025-1033. doi: 10.1007/s11739-025-03902-w. Epub 2025 Mar 14.
6
The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial.恩格列净对2型糖尿病患者非酒精性脂肪性肝病相关参数的影响：一项随机对照试验。
BMC Endocr Disord. 2025 Feb 26;25(1):52. doi: 10.1186/s12902-025-01882-8.
7
Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021.2010年至2021年代谢功能障碍相关脂肪性肝病的全球负担
JHEP Rep. 2024 Nov 14;7(3):101271. doi: 10.1016/j.jhepr.2024.101271. eCollection 2025 Mar.
8
Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes Mellitus.肠道微生物群可预测非糖尿病性脂肪性肝病患者对恩格列净的治疗反应。
Liver Int. 2025 Mar;45(3):e70023. doi: 10.1111/liv.70023.
9
Lubiprostone Reduces Fat Content on MRI-PDFF in Patients With MASLD: A 48-Week Randomised Controlled Trial.鲁比前列酮可降低非酒精性脂肪性肝病患者MRI-PDFF的脂肪含量：一项48周的随机对照试验。
Aliment Pharmacol Ther. 2025 Feb;61(4):628-635. doi: 10.1111/apt.18478. Epub 2025 Jan 2.
10
Reply: Aspirin and GLP-1RAs-The missing confounders of empagliflozin for MASLD without diabetes mellitus?回复：阿司匹林与胰高血糖素样肽-1受体激动剂——恩格列净治疗非糖尿病性代谢相关脂肪性肝病时被遗漏的混杂因素？
Hepatology. 2025 Jan 1;81(1):E23. doi: 10.1097/HEP.0000000000001034. Epub 2024 Jul 24.